Overexpression of HER2 plays a significant role in the progression in a variety of solid tumors, whereas overexpression in breast cancer is most renowned.[156] Eloy and colleagues coated PTX and rapamycin (RAP) coloaded liposomes with an anti‐HER2 monoclonal antibody, and evaluated the therapeutic efficacy in HER2‐positive tumor‐bearing mice, as compared to control solution, free PTX/RAP solution, and PTX/RAP coloaded liposomes. Here, ERBB2 is linked to breast carcinoma.